United posts positive data for inhaled PAH drug

United Therapeutics shares were on the rise after the company announced positive results from a Phase III trial of Viveta, an inhaled version of pulmonary arterial hypertension (PAH) drug Remodulin. Patients taking Viveta were able to walk farther in six minutes than those taking placebo. Analysts expect United to file an NDA sometime in June. If approved, Viveta will compete with Actelion's Ventavis, the only other inhaled PAH drug on the market.

- read the AP report

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.